We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more OK
Roche Menu Search Global Web Site : Presse Suisse

You are here:

Roche Language: DE Language: EN
  • Home
  • Roche Suisse
  • Sites
  • Pharma
  • Diagnostics
  • Presse Suisse
  • Carrière
media-ch-1920

Presse Suisse

Communiqué de presse Suisse

All
Published on: 14 juillet 2020

ENSPRYNG® (Satralizumab) de Roche homologué en Suisse pour le traitement des Troubles du Spectre de la Neuromyélite Optique (Neuromyelitis Optica Spectrum Disorder, NMOSD)

 plus
Tweets by roche_schweiz
image

Subscribe to Roche news

Get the latest news and updates to your inbox.

 plus
image

Medienstelle

Contact details for media inquiries.

 plus
image

Roche Suisse

Un leader aussi bien international que national.

 plus
image

Media library

Browse and download multimedia resources including images and videos

 plus
Share
  • Share via email
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share on Google+
  • Share on Xing
Close
  • © 2020 F. Hoffmann-La Roche Ltd
  • 14.08.2020
  • Mentions Légales
  • La protection des données personnelles

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

  • Twitter
  • LinkedIn
  • Facebook
  • YouTube
  • Pinterest